FAMILY ADAPTATION TO NEWBORN SCREENING FOR FRAGILE X SYNDROME
家庭对新生儿脆性 X 综合征筛查的适应
基本信息
- 批准号:7482836
- 负责人:
- 金额:$ 26.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-07-01 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcademyAdverse eventAffectAgeAmericanAnxietyBehaviorBirthChildConditionConsentDevelopmentDiagnosisDisadvantagedDisclosureEarly InterventionEthnic groupEvolutionFamilyFamily memberFemaleFragile X SyndromeFrustrationHealthHealth ProfessionalHealthcare SystemsInfantInheritedIntellectual functioning disabilityLearningMedicalMental HealthMinorMutationNeonatal ScreeningNewborn InfantOutcomeParent-Child RelationsParentsPediatricsProfessional OrganizationsReportingRiskScreening ResultScreening procedureTestingTimeVariantgirlsimprovedmaleprototypereproductive
项目摘要
A. SPECIFIC AIMS
Fragile X syndrome (FXS) is the most common inherited form of intellectual disability. However, because
phenotypic features are not evident at birth, FXS must be discerned through abnormalities in development or
behavior. Parents typically go through an extended "odyssey" before FXS is diagnosed (Bailey, Skinner,
Hatton, & Roberts, 2000; Bailey, Skinner, & Sparkman, 2003). The average age of diagnosis is 32-36 months
for full mutation males, and usually later for girls, since females are more mildly affected. As a result, children
miss the opportunity to participate in early intervention and parents often have additional children with FXS
without knowing reproductive risk.
Newborn screening would provide parents the opportunity to learn about their child's FXS status and their own
reproductive risk, in addition to other likely benefits (Bailey, 2004; Bailey, Skinner, & Warren, 2005; Bailey,
Beskow, Davis, & Skinner, 2006). However, concerns have been raised, including lack of a treatment, consent
issues, possible parent anxiety or disrupted parent-child relations, carrier disclosure, and limited state capacity
to support families (Bailey et al., accepted pending minor revisions). Thus newborn screening for FXS is
controversial. Parents report frustration with professionals and the health care system, consider advantages of
screening more likely than disadvantages, and have a broad view of "benefit" and "treatment" (Bailey et al.,
2006; Bailey, Skinner, & Sparkman, 2003; Skinner, Sparkman, & Bailey, 2003). These and other studies (e.g.,
Campbell & Ross, 2003; Davidson et al., 2000; Helton et al., 1991; Whitehead & Strange, 2006) show that
parents strongly support voluntary expanded newborn screening. However, professionals generally insist on
screening only for conditions with clear medical treatments that improve health outcomes (Botkin et al., 2006;
Natowicz, 2005). Professional organizations oppose carrier testing for infants, arguing that screening should
only be done if there is proven medical benefit to the infant (American Academy of Pediatrics, 2000;
ASHG/ACMG, 1995).
Fragile X syndrome is an excellent prototype for studying issues that will arise in an era of technical capacity
for greatly expanded newborn screening. Project 3 focuses on family adaptation to newborn screening for FXS.
The study will provide important information about the consequences of screening for both carriers and
children with the full mutation FXS.
A. 具体目标
脆性 X 综合征 (FXS) 是最常见的智力障碍遗传形式。然而,因为
表型特征在出生时并不明显,FXS 必须通过发育或发育异常来辨别
行为。在诊断出 FXS 之前,父母通常要经历一段漫长的“冒险之旅”(Bailey、Skinner、
哈顿和罗伯茨,2000;贝利、斯金纳和斯帕克曼,2003)。平均诊断年龄为32-36个月
对于完全突变的男性,通常对女孩来说要晚一些,因为女性受到的影响更轻微。结果,孩子们
错过参与早期干预的机会,并且父母经常有额外的患有 FXS 的孩子
在不了解生殖风险的情况下。
新生儿筛查将为父母提供了解孩子的 FXS 状态以及他们自己的机会
除了其他可能的好处外,还存在生殖风险(Bailey,2004;Bailey、Skinner 和 Warren,2005;Bailey,
贝斯科、戴维斯和斯金纳,2006)。然而,人们也提出了一些担忧,包括缺乏治疗、同意
问题、可能的家长焦虑或亲子关系中断、承运人披露以及国家能力有限
支持家庭(Bailey 等人,接受待定的小修改)。因此,新生儿 FXS 筛查是
有争议的。家长对专业人士和医疗保健系统表示失望,考虑以下优点:
筛查的可能性大于缺点,并且对“益处”和“治疗”有广泛的看法(Bailey 等人,
2006年;贝利、斯金纳和斯帕克曼,2003 年;斯金纳、斯帕克曼和贝利,2003)。这些和其他研究(例如,
坎贝尔和罗斯,2003;戴维森等人,2000;赫尔顿等人,1991; Whitehead & Strange, 2006)表明
父母强烈支持自愿扩大新生儿筛查。但专业人士普遍坚持
仅筛查可改善健康结果的明确医疗方法的病症(Botkin 等人,2006 年;
纳托维奇,2005)。专业组织反对对婴儿进行携带者检测,认为筛查应该
仅当已证明对婴儿有医疗益处时才可进行(美国儿科学会,2000 年;
ASHG/ACMG,1995)。
脆性 X 综合征是研究技术能力时代出现的问题的绝佳原型
大大扩大新生儿筛查范围。项目 3 重点关注家庭对 FXS 新生儿筛查的适应。
该研究将提供有关携带者和携带者筛查后果的重要信息。
具有 FXS 完全突变的儿童。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Donald B Bailey其他文献
Donald B Bailey的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Donald B Bailey', 18)}}的其他基金
Child and Family Consequences of Congenital Zika Syndrome in Brazil
巴西先天性寨卡综合症对儿童和家庭的影响
- 批准号:
9912805 - 财政年份:2017
- 资助金额:
$ 26.77万 - 项目类别:
Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns
早期检查:促进新生儿症状前临床试验的协作创新
- 批准号:
9975249 - 财政年份:2016
- 资助金额:
$ 26.77万 - 项目类别:
NORTH CAROLINA: PILOT TEST AND DEVELOPMENT OF NEWBORN SCREENING PROGRAM CAPACITY
北卡罗来纳州:新生儿筛查计划能力的试点测试和发展
- 批准号:
9134040 - 财政年份:2015
- 资助金额:
$ 26.77万 - 项目类别:
Decisional Capacity and Informed Consent in Fragile X Syndrome
脆性 X 综合征的决策能力和知情同意
- 批准号:
8437309 - 财政年份:2012
- 资助金额:
$ 26.77万 - 项目类别:
Decisional Capacity and Informed Consent in Fragile X Syndrome
脆性 X 综合征的决策能力和知情同意
- 批准号:
8554306 - 财政年份:2012
- 资助金额:
$ 26.77万 - 项目类别:
Decisional Capacity and Informed Consent in Fragile X Syndrome
脆性 X 综合征的决策能力和知情同意
- 批准号:
8699808 - 财政年份:2012
- 资助金额:
$ 26.77万 - 项目类别:
ELSI Scale-Up: Large Sample Gene Discovery & Disclosure
ELSI 放大:大样本基因发现
- 批准号:
6831405 - 财政年份:2004
- 资助金额:
$ 26.77万 - 项目类别:
ELSI Scale-Up: Large Sample Gene Discovery & Disclosure
ELSI 放大:大样本基因发现
- 批准号:
6944520 - 财政年份:2004
- 资助金额:
$ 26.77万 - 项目类别:
ELSI Scale-Up: Large Sample Gene Discovery & Disclosure
ELSI 放大:大样本基因发现
- 批准号:
7273900 - 财政年份:2004
- 资助金额:
$ 26.77万 - 项目类别:
相似国自然基金
基于中医舌诊参数及糖脂代谢指标的PCI术后再发心血管不良事件时间序列预测模型研究
- 批准号:82374336
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于效用错位视角的医疗不良事件管理政策的引导体系优化研究
- 批准号:72304012
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于人工智能和多模态信息预测复杂下肢动脉病变术后不良事件的算法机制研究
- 批准号:82370499
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于几何形态与生物力学分析预测腹主动脉瘤腔内治疗术后锚定区相关不良事件
- 批准号:82300542
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
GNB3联合光谱CT冠周脂肪组学预警ACS后心血管不良事件的模型构建
- 批准号:82302186
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
UNderstanding the Delivery of Low-Value CAre To CHildren and the Barriers to De-Implementation (UN-LATCH)
了解向儿童提供低价值护理以及取消实施的障碍 (UN-LATCH)
- 批准号:
10649811 - 财政年份:2023
- 资助金额:
$ 26.77万 - 项目类别:
Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
评估在社区肿瘤诊所接受治疗的一组癌症患者中大麻和大麻素使用的益处和危害
- 批准号:
10792076 - 财政年份:2023
- 资助金额:
$ 26.77万 - 项目类别:
Implementation of Communication Disability Collection and Accommodations in Primary Care Settings
在初级保健机构中实施沟通障碍收集和住宿
- 批准号:
10586694 - 财政年份:2022
- 资助金额:
$ 26.77万 - 项目类别:
Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice: A PBRN Clinical Trial
确定牙科实践中牙周辅助抗生素的适应症:PBRN 临床试验
- 批准号:
10448940 - 财政年份:2022
- 资助金额:
$ 26.77万 - 项目类别:
Implementation of Communication Disability Collection and Accommodations in Primary Care Settings
在初级保健机构中实施沟通障碍收集和住宿
- 批准号:
10705832 - 财政年份:2022
- 资助金额:
$ 26.77万 - 项目类别: